ArticleInternational journal of hematology2022

Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience.

Adrianna Spałek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.